News

NEW HAVEN, Conn., Dec. 2, 2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance … [Read more...] about Kleo Pharmaceuticals to Present at Piper Jaffray 31st Annual Healthcare Conference

New Haven, CT, Oct. 15, 2019 – Kleo Pharmaceuticals Inc., a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics, … [Read more...] about Kleo Pharmaceuticals to Present at 2019 BIO Investor Forum

In 2012, five years before he became the CSO of Bristol-Myers Squibb, Thomas Lynch began hearing from a Yale colleague about new ways to fight cancer with antibodies. Now that colleague, David … [Read more...] about Thomas Lynch chairs former colleague’s cancer startup

NEW HAVEN, Conn., Nov. 6, 2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance … [Read more...] about Kleo Pharmaceuticals Presents Preclinical Data Supporting Development of its CD38-ARM™, a Novel Immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting

NEW HAVEN, Conn., Nov. 4, 2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., a unique immuno-oncology company developing next-generation synthetic bispecific compounds designed to emulate or enhance the … [Read more...] about Kleo Pharmaceuticals Appoints Thomas J. Lynch, Jr., MD, as Chairman of the Board